X

Drug Design, Development and Therapy

Drug Design, Development and Therapy
Inhibitory Effects of Periplocin on Lymphoma Cells: A Network Pharmacology Approach and Experimental Validation

The effects of periplocin on lymphoma and the underlying mechanisms of action remain unclear.

Drug Design, Development and Therapy
03/26/2021
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

Long-term follow-up is needed, but zanubrutinib holds promise to be an effective therapy for CLL with a manageable side effect profile and will be an exciting addition to the treatment paradigm.

Drug Design, Development and Therapy
03/02/2021
Current Understanding on Perioperative Management in Lung Cancer: Implications for Anesthetic Considerations

This study summarizes the effects of anesthetic management and its related substances on lung cancer.

Drug Design, Development and Therapy
02/25/2021
The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children

This study aims to evaluate the effectiveness of Ruxolitinib for acute/chronic graft-versus-host disease in children.

Drug Design, Development and Therapy
02/22/2021
Subscribe to Drug Design, Development and Therapy

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39